Allozyne raises $30 million and names new CEO
The funding will also accelerate the preclinical development of a second program as well as further exploit the company’s proprietary technology platform. MPM Capital led the financing with
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.
In an established animal model, anaphylactoid clinical reactions were observed following Taxotere administration, including decreased respiration, swelling and tremors. Furthermore, decreases in blood pressure and increases in histamine